Just in reply to @Boffin99 (hotcopper reply function not linking...

Just in reply to @Boffin99 (hotcopper reply function not linking to your last post for some reason)….

I’d be happy with that too if I knew what threshold has been set for the percentage reduction in uPCR as the criteria for being clinically meaningful.

As with Travere’s Phase 3 trial, our Part 2 analysis for eGFR slope is going to be the most challenging endpoint to meet on this trial. And this will hinge on the magnitude of uPCR reduction shown at the Part 1 analysis.

We would all be a lot more confident going into Part 2 if the total reduction of uPCR on DMX including the baseline reduction from Irbesartan was greater than 50-60% (as a mean result) than if we were less than 50% for example.

I know we have a different mechanism of action to Travere and a two-pronged attack. But if Sparsentan didn’t show clinically meaningful reduction to eGFR when they had a total reduction of 50% uPCR, then you would think that it’s going to be important for us to show a combined benefit from Irbesartan + DMX of well over this figure to give us a good chance of success at Part 2 and the final result.